This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-20. Anything still debated is marked as such rather than presented as settled.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
== Definition == Polycythemia is defined as serum hematocrit (Hct) or hemoglobin (HgB) exceeding normal ranges expected for age and gender, typically Hct >49% in healthy adult men and >48% in women, or HgB >16.5 g/dL in men or >16.0 g/dL in women. The definition is different for neonates and varies by age in children.
In the late 19th century anorexia nervosa became widely accepted by the medical profession as a recognized condition, with mentions in the medical literature notably arising from the Salpêtrière clinic in Paris by physicians such as Jean-Martin Charcot. Awareness of the condition was largely limited to the medical profession until the latter part of the 20th century, when German-American psychoanalyst Hilde Bruch published The Golden Cage: the Enigma of Anorexia Nervosa in 1978. Despite major advances in neuroscience, Bruch's theories tend to dominate popular thinking. A further important event was the death of the popular singer and drummer Karen Carpenter in 1983, which prompted widespread ongoing media coverage of eating disorders.
The new 25th district runs from northern Arlington and southern and eastern Fort Worth in Tarrant County, whose portion is the only portion of the district considered even remotely competitive (and in fact, favorable) to Democrats, out to several heavily Republican exurban and rural areas south and west of Fort Worth and just east of Abilene, including Cleburne, Granbury, Willow Park, Mineral Wells, Stephenville, Jacksboro and Eastland. Due to redistricting, the district has two incumbents, Republican Roger Williams, who was re-elected unopposed in 2024, and Democrat Marc Veasey, who was re-elected with 68.7% of the vote in 2024. Veasey, the incumbent from the old 33rd district (see below) decided to not seek reelection, instead pursuing a short-lived bid for Tarrant County judge before dropping out of that race. Donald Trump won 61.4% of the vote in this district in 2024, which also saw Ted Cruz win 58.4% of the vote.
=== Books === Boitano, Scott; Brooks, Heddwen L.; Barman, Susan M.; Barrett, Kim E. (2016). Ganong's Review of Medical Physiology. McGraw-Hill Education. ISBN 978-0-07-182510-8. Susan Standring, ed. (2008). Gray's anatomy: the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. ISBN 978-0-8089-2371-8. Cole, Laurence A.; Kramer, Peter R. (2016). Human Physiology, Biochemistry and Basic Medicine. Amsterdam: Academic Press. ISBN 978-0-12-803699-0.
Food and Drug Administration (FDA) on 24 July 2015, and evolocumab (Repatha, Amgen), approved on 27 August 2015; both were also authorised in the European Union in 2015. Inclisiran (Leqvio, Novartis), a small interfering RNA (siRNA) that reduces PCSK9 production in the liver and is administered by twice-yearly injection, was subsequently approved by the European Medicines Agency in December 2020 and by the FDA in December 2021. PCSK9 inhibitors have been shown to significantly reduce LDL-C levels and increase HDL-C levels significantly. They were found to lower the incidence of myocardial infarction and stroke in individuals at high cardiovascular risk (over 15% using PREDICT cardiovascular disease calculator), such as those with at least five risk factors, established cardiovascular disease, or hereditary lipid disorders without cardiovascular risk factor, but not in those at low to moderate risk. A 2023 meta-analysis has indicated that alirocumab may reduce all-cause mortality, whereas evolocumab has no significant effect on all-cause mortality. The efficacy of bococizumab remains unclear, as its development was discontinued by Pfizer in 2016. The most recent guidelines for cholesterol management from the American Heart Association and American College of Cardiology now provide guidance for when PCSK9 inhibitors should be considered, particularly focusing on cases in which maximally tolerated statin and ezetimibe fail to achieve goal LDL reduction. A possible side effect of the monoclonal antibody might be irritation at the injection site.
Sources: en.wikipedia.org
The agreement specified that this agreement was only with Amat-Mamu, and no other person could lay claim to Belessunu's estate by providing for her. Two years after the agreement was made, two of Belessunu's cousins and fellow nadītus—Amat-Šamaš and Nīši-īnīšu—laid claim to the fields. The mayor of Sippar, Zimri-Erah, ruled that the inheritance was rightfully Belessunu's. The cousins were penalized for making a false claim over property, and they were forced to give Amat-Mamu a tablet that relinquished their claims. Professor Rivkah Harris speculated that Belessunu passed over her cousins in favor of Amat-Mamu because Amat-Mamu was a member of a wealthy family and therefore better able to support Belessunu during her life.
In the UK, the BBC's Ceefax service gave the film a mixed review. Remarked the unnamed critic who reviewed the film for the teletext service: This sequel is disappointing and inferior to the 1996 original, but it still provides exuberant fun. The effects are so seamless and Eddie Murphy's performances as the Klumps so distinct from one another, that you really do forget it's all one actor. Janet Jackson will never be a great actress, but she pulls off her role with natural skill, something Madonna lacks to an embarrassing degree. The film's weakness is in its failure to fully realise the potential of some of its own best jokes. A restaurant scene mostly misfires simply because a lot of the dialogue is incomprehensible and the characters all talk over each other. In the original, Buddy Love was funny and charismatic. Here, he's a loud irritant, so it's just as well that the film focuses on the other Klumps.
Moreover, high inducers of ROS such as 2-deoxy-D-glucose and carbohydrate-based inducers of cellular stress induce cancer cell death more potently because they exploit the cancer cell's high avidity for sugars.
Cocaine dependence develops after even brief periods of regular cocaine use. About 25% of adults with attention deficit hyperactivity disorder (ADHD) use cocaine, and 10% develop a cocaine use disorder during their lifetime. Because cocaine use can worsen health outcomes, adults with ADHD should be screened for cocaine use disorder and referred for treatment if needed. Cocaine-dependent patients with high neuroticism scores are more likely to experience cocaine-induced psychotic symptoms, regardless of other drug use factors, making personality assessment important for risk identification and patient warning. Cocaine withdrawal symptoms group into two types: depressive (e.g., depression, craving, insomnia) and somatic (e.g., increased appetite, fatigue). Depressive symptoms are linked to worse outcomes like longer depression, treatment, and risky behaviors.
Sources: en.wikipedia.org
== History == The term "narcotic" is believed to have been coined by the Greek physician Galen to refer to agents that numb or deaden, causing paralysis or loss of feeling. It is based on the Greek word ναρκωσις (narcosis), the term used by Hippocrates for the process of numbing or the numbed state. Galen listed mandrake root, altercus (eclata), seeds, and poppy juice (opium) as the chief examples. It originally referred to any substance that relieved pain, dulled the senses, or induced sleep. Now, the term is used in many ways. Some people might define narcotics as substances that bind at opioid receptors (cellular membrane proteins activated by substances like heroin or morphine), while others refer to any illicit substance as a narcotic. From a U.S. legal perspective, narcotics refer to opium, opium derivatives, and their semi-synthetic substitutes, though in U.S. law, due to its numbing properties, cocaine is also considered a narcotic. The definition encompassing "any illegal drug" was first recorded in 1926. Its first use as an adjective is first attested to c. 1600. There are many different types of narcotics. The two most common forms of narcotic drugs are morphine and codeine. Both are synthesized from opium for medicinal use. The most commonly used drug for recreational purposes created from opium is heroin. Synthesized drugs created with an opium base for use in pain management are fentanyl, oxycodone, tramadol, pethidine (Demerol), hydrocodone, methadone, and hydromorphone. New forms of existing pain medications are being created regularly.
==== Methylnaltrexone bromide ==== Methylnaltrexone bromide is the bromide salt form of methylnaltrexone, a quaternary methyl derivative of noroxymorphone. The methyl group and the quaternary salt formation increase the polarity and reduce the lipid solubility thereby restricts the blood–brain-barrier penetration. Methylnaltrexone has eight times higher affinity for MOR than for κ-opioid receptor (KOR) and δ-opioid receptor (DOR). Naltrexone forms interaction with Asp147 and Tyr148 along with a hydrogen bond with Lys233.
=== Structural proteomics === A third area of Borchers' research is structural proteomics, which combines protein chemistry methods—such as cross-linking, hydrogen–deuterium exchange and photoaffinity labelling—with mass spectrometry and molecular modelling to study protein structure and interactions. This work includes the study of protein folding and misfolding associated with diseases such as Parkinson's disease and cystic fibrosis. In 2011, Borchers co-founded the Symposium on Structural Proteomics with Evgeniy Petrotchenko, and the two have co-organized the international meeting annually since.
On 7 December 1941, Japan attacked the United States at Pearl Harbor, bringing it too into the war on the side of the Allies. China also joined the Allies, as did most of the rest of the world. China was in turmoil at the time and attacked Japanese armies through guerrilla-type warfare. By the beginning of 1942, the alignment of the major combatants was as follows: the British Commonwealth, the Soviet Union, and the United States were fighting Germany and Italy; China, the British Commonwealth, and the United States were fighting Japan. The United Kingdom, the United States, the Soviet Union, and China were referred to as a "trusteeship of the powerful" during World War II and were recognized as the Allied "Big Four" in the Declaration by United Nations. These four countries were considered the "Four Policemen" or "Four Sheriffs" of the Allies and were the primary victors of World War II. Battles raged across all of Europe, in the north Atlantic Ocean, across North Africa, throughout Southeast Asia, throughout China, across the Pacific Ocean, and in the air over Japan. Italy surrendered in September 1943 and was split into a northern Germany-occupied puppet state and an Allies-friendly state in the south; Germany surrendered in May 1945. Following the atomic bombings of Hiroshima and Nagasaki, Japan surrendered, marking the end of the war on 2 September 1945. It is possible that around 62 million people died in the war; estimates vary greatly.
Enzyme linked receptors include Receptor tyrosine kinases (RTKs), serine/threonine-specific protein kinase, as in bone morphogenetic protein and guanylate cyclase, as in atrial natriuretic factor receptor. Of the RTKs, 20 classes have been identified, with 58 different RTKs as members. Some examples are shown below:
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.